Trial Profile
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs INCB-81776 (Primary) ; Retifanlimab (Primary)
- Indications Acute myeloid leukaemia; Adenocarcinoma; Advanced breast cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 11 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 11 Dec 2023 Planned primary completion date changed from 2 Nov 2023 to 30 Nov 2024.
- 18 Jul 2023 Planned End Date changed from 2 Dec 2023 to 31 Dec 2023.